Addressing Asbestos Contamination Risks in Pharmaceutical Powders

Overview

A recent regulatory shift is prompting heightened awareness around asbestos contamination in pharmaceutical powders, particularly those containing talc. This development stems from findings in the cosmetics industry, where asbestos was discovered in talc-based products. As the FDA tightens regulations, pharmaceutical companies must act swiftly to ensure compliance with new testing and documentation standards. This article outlines the origin of the issue, the risks involved, and how PAX-it Extended Security software can support your organization’s need for 21 CFR Part 11 compliance when incorporating digital imaging into asbestos identification.

How This Issue Emerged

The presence of asbestos in pharmaceutical powders is primarily linked to talc, a common excipient that is often found near asbestos in natural deposits. This geological proximity raises the risk of inadvertent contamination. Compounding this risk is the fact that historical testing standards—such as the USP < 901 > “absence of asbestos” method —were not sensitive enough to detect trace levels of asbestos, prompting concern among regulators.

The issue gained momentum after asbestos was found in several talc-based cosmetic products, leading the FDA to establish the Interagency Working Group on Asbestos in Consumer Products (IWGACP) in 2018. In response, the FDA hosted public workshops in 2020 and published peer-reviewed guidance in 2022. The passage of the Modernization of Cosmetics Regulation Act (MoCRA) in December 2022 further expanded the FDA’s authority, culminating in a proposed rule in December 2024 that mandates testing for asbestos in talc-containing products under MoCRA Section 3505.

The Current Risk Landscape

Under the FDA’s proposed rule, testing standards are stricter than ever. The agency now requires dual-mode testing—polarized light microscopy (PLM) and transmission electron microscopy (TEM) with energy-dispersive X-ray spectroscopy (EDS) and selected area electron diffraction (SAED). Even a single asbestos fiber detected by these methods would render a batch adulterated.

While the rule initially applies to cosmetics, it is already influencing pharmaceutical manufacturing practices, especially for talc-based powders. Companies must now maintain detailed, auditable records for each lot, including testing data and supplier Certificates of Analysis (COAs). The FDA has made it clear that relying solely on legacy testing methods is no longer acceptable.

Mitigation Efforts Underway

To stay compliant, many manufacturers are adopting enhanced analytical protocols. This typically includes implementing both PLM and electron microscopy to ensure asbestos is not present. In some cases, companies may rely on supplier-provided COAs, but only if those suppliers use FDA-accepted methods. Verification of these COAs is crucial.

In parallel, organizations are strengthening their documentation processes to support future audits and inspections. This includes not only storing test results and images but also linking them to specific lots and suppliers for full traceability.

How PAX-it Supports CFR Part 11 Compliance in This Context

PAX-it provides a comprehensive digital microscopy solution to help pharmaceutical and cosmetic manufacturers capturing images of test results meet the demands of FDA 21 CFR Part 11 compliance, particularly in response to new asbestos testing regulations. Here is how our platform supports your compliance needs:

Compliance Requirement –> PAX-it Capability

• Supplier Documentation –> Capture and manage COAs, supplier qualifications, and supporting records.
• Test Result Archiving –> Store raw test results, images, and metadata with full audit trails.
• Batch Traceability –> Associate test data and COAs with specific product lots for complete genealogy.
• Electronic Records & Signatures –> Secure time-stamped edits and electronic approvals.
• Long-Term Retention & Access –> Configure automated archiving and ensure easy data retrieval.
• Change Control & CAPA –> Log and manage deviations, corrective actions, and document updates.

Conclusion

With the FDA’s evolving stance on asbestos in both cosmetic and pharmaceutical products, rigorous testing and transparent documentation are no longer optional—they are mandatory. Companies that fail to adapt risk product recalls, regulatory penalties, and reputational harm. PAX-it’s 21 CFR Part 11 software offers an end-to-end solution for managing the complexity of compliance when capturing digital images of asbestos tests from microscopes, ensuring your data is traceable, secure, and audit-ready.

Learn more about emerging regulatory trends and explore our compliance solutions at